JP2019515050A - 複合セロリ種子槐米抽出物及びその医薬用途 - Google Patents
複合セロリ種子槐米抽出物及びその医薬用途 Download PDFInfo
- Publication number
- JP2019515050A JP2019515050A JP2019512033A JP2019512033A JP2019515050A JP 2019515050 A JP2019515050 A JP 2019515050A JP 2019512033 A JP2019512033 A JP 2019512033A JP 2019512033 A JP2019512033 A JP 2019512033A JP 2019515050 A JP2019515050 A JP 2019515050A
- Authority
- JP
- Japan
- Prior art keywords
- celery seed
- rice
- extract
- combined
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 44
- 235000009566 rice Nutrition 0.000 title claims abstract description 44
- 239000001387 apium graveolens Substances 0.000 title claims abstract description 34
- 240000000249 Morus alba Species 0.000 title claims abstract description 18
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 18
- 240000007594 Oryza sativa Species 0.000 title abstract description 36
- 240000007087 Apium graveolens Species 0.000 claims abstract description 26
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 25
- 235000010591 Appio Nutrition 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 201000005569 Gout Diseases 0.000 claims abstract description 21
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 244000236458 Panicum colonum Species 0.000 claims abstract description 4
- 235000015225 Panicum colonum Nutrition 0.000 claims abstract description 4
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 3
- 210000002966 serum Anatomy 0.000 claims description 50
- 239000003814 drug Substances 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 24
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 23
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 19
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002137 ultrasound extraction Methods 0.000 claims description 5
- 108010005440 Guanosine deaminase Proteins 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000005456 alcohol based solvent Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000209094 Oryza Species 0.000 claims 8
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 65
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 63
- 229940116269 uric acid Drugs 0.000 description 63
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 56
- 241000700159 Rattus Species 0.000 description 44
- 238000002474 experimental method Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 31
- 229940109239 creatinine Drugs 0.000 description 28
- 230000036772 blood pressure Effects 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- 230000002485 urinary effect Effects 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 210000002700 urine Anatomy 0.000 description 15
- 108010012029 Guanine Deaminase Proteins 0.000 description 14
- 102000013587 Guanine deaminase Human genes 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 239000007884 disintegrant Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 9
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 7
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 7
- 235000005493 rutin Nutrition 0.000 description 7
- 229960004555 rutoside Drugs 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 229930091371 Fructose Natural products 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 6
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 5
- 229960003459 allopurinol Drugs 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229960002529 benzbromarone Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- -1 flavonoid compounds Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 3
- 244000046101 Sophora japonica Species 0.000 description 3
- 235000010586 Sophora japonica Nutrition 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008085 renal dysfunction Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 229940116731 Uricosuric agent Drugs 0.000 description 2
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 2
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960002708 antigout preparations Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003383 uricosuric agent Substances 0.000 description 2
- FXLJDRXREUZRIC-BAOOBMCLSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO FXLJDRXREUZRIC-BAOOBMCLSA-N 0.000 description 1
- 102100030841 AT-rich interactive domain-containing protein 4A Human genes 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 235000002764 Apium graveolens Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000792933 Homo sapiens AT-rich interactive domain-containing protein 4A Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- NTFQHAKUNDRGJR-UHFFFAOYSA-N Sophoradiol Natural products CC1(C)CC(O)C2(C)CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1 NTFQHAKUNDRGJR-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000001556 apium graveolens l. seed extract Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229940116732 celery seed extract Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical group [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 1
- ZPCAZHPYLUKSMY-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZPCAZHPYLUKSMY-UHFFFAOYSA-M 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- ZEGUWBQDYDXBNS-FVFJQADASA-N sophoradiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)[C@H](O)CC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C ZEGUWBQDYDXBNS-FVFJQADASA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
実施例1
実施例2
実施例3
実施例4 錠剤の調製
微結晶セルロース(希釈剤) 150mg
HPMC(結合剤) 5mg
架橋ポリビニルピロリドン(崩壊剤) 20mg
コロイド状二酸化ケイ素(潤滑剤) 5mg
実施例5 微丸剤の調製
微結晶セルロース(希釈剤) 150mg
HPMC(結合剤) 5mg
架橋ポリビニルピロリドン(崩壊剤) 20mg
コロイド状二酸化ケイ素(潤滑剤) 5mg
実験動物
北京市斯貝福動物実験センターから購入し、実験動物品質合格証番号が11401500006019、動物室許可証番号がSCXK(京)2011−0004である雄性SDラット。
SDラットを1群ごとに少なくとも10匹で無作為に分けた。各動物に対して、投与前の5日間は毎朝10時に血圧を測定した(RBP−1型ラット尾動脈血圧計、中日友好臨床医学研究所)。この群の全ての動物の5日間の血圧の平均値を、投与前の血圧(B0)とした。本発明の抽出物投与群に、総生薬重量(セロリ種子及び槐米の両者の合計重量)で5g/kg/dayの投与量で、毎朝10時に1回投与し(投与前に血圧を測定し)、10日間連続的に投与した後、最終回で測定された血圧平均値(B1)を計算した。下式により、ラットの平均血圧降下幅を計算した。
平均血圧降下幅(%)=[(B0−B1)÷B0]×100%。
抽出物1の平均血圧降下幅(%)は8%、抽出物2の平均血圧降下幅(%)は12%、抽出物3の平均血圧降下幅(%)は9%であった。
1)実験動物
北京市斯貝福動物実験センターから購入し、実験動物品質合格証番号が11401500006019、動物室許可証番号がSCXK(京)2011−0004であり、体重が200±20gであり、計84匹の雄性SDラット。
陽性対照薬:ベンズブロマロン、Excella GmbH製、規格:50mg/錠剤、ロット番号:150201。
検出試薬キット:中生北控生物科技股フン有限公司製の尿酸(UA)検出試薬キット、南京建成生物工程研究所製のクレアチニン(CR)検出試薬キット、南京建成生物工程研究所製のキサンチンオキシダーゼ(XOD)検出試薬キット、南京建成生物工程研究所製のアデノシンデアミナーゼ(ADA)検出試薬キット、南京建成生物工程研究所製の尿素窒素(BUN)検出試薬キット、南京建成生物工程研究所製のグアニンデアミナーゼ(GuDa)検出試薬キット。
モデル作製用薬剤:米国AMRESCO社製、ロット番号が2563C076であるD−フルクトース、Sigma社から購入し、ロット番号が060M1199Vであるヒポキサンチン、Bio Dee社から購入し、ロット番号がN4126であるニコチン酸。
LJX−II遠心機(上海医用分析儀器廠)、低温高速遠心機(Sigma社)、SHZ88−1型卓上型水槽恒温発振器水槽(太倉市光明実験分析儀器廠)、SHIMADZUBl−220H電子天秤、Sunriseマイクロプレートリーダー(Tecan、オーストリア)。
実験モデル作製方法は、発表されている研究論文『連続高フルクトース飲水のラット尿酸レベルへの影響及びその疾患メカニズム』(李麗玉、林志健、張氷等、連続高フルクトース飲水のラット尿酸レベルへの影響及びその疾患メカニズム、中華臨床栄養雑誌、2014、22(6):368−374)、文献『マウス高尿酸血症モデルに関する予備的研究』(金沈鋭、鄭軍、劉紹唐、マウス高尿酸血症モデルに関する予備的研究、成都中医薬大学学報、1999、22(01):50−51+65)、及び『Eeffcts of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis』(Ji Wei,Zhu Xuan−xuan,Tan Wen−feng,Lu Yan.Effects of Rebixiao granules on blood uric acid in patients with repeatedly attacking acute gouty arthritis.Chinese Journal of Integrative Medicine,2005,11(1):15−21.)を参照した。
乱数表に基づき、SDラットを体重によって層別化し、各層を乱数表により正常群(10匹)、フルクトースモデル作製群(50匹)、プリンモデル作製群(24匹)に分けた。正常群に水道水を与え、フルクトースモデル作製群に10%(w/v)フルクトース水を与えてモデルを作製し、プリンモデル作製群に水道水を飲ませ、体重別にヒポキサンチン500mg/kg+ニコチン酸100mg/kgを毎日1回強制経口投与し、強制経口投与容量は10ml/kgであった。ラットの摂食量、飲水量を毎日に記録し、7日間ごとに体重を秤量し、翌日に尻尾の先端を切って採血した。
実験期間中、7日間ごとに動物の体重を秤量して記録し、尾静脈から採血し、遠心分離により血清を分離した。血清尿酸(UA)、尿素窒素(BUN)、クレアチニン(CRE)、キサンチンオキシダーゼ(XOD)、アデノシンデアミナーゼ(ADA)及びグアニンデアミナーゼ(GuDa)を検出した。実験の35日目にラットの24時間尿を取り、尿量を測定し、pHを測定し、尿中尿酸、尿中クレアチニン、尿中尿素窒素レベルを検出した。実験終了後にラットを殺し、右腎を取って体重を秤量した。
I.ウリカーゼ比色法による血清尿酸及び尿中尿酸の検出:尿酸をウリカーゼの触媒作用下で、アラントイン及び過酸化水素(H2O2)を生成し、H2O2と4−アミノアンチピリン(4−AAP)及びN−エチル−N−(2−ヒドロキシ−3−スルホプロピル)−3−メチルアニリン(TOOS)は、ペルオキシダーゼ(POD)の触媒作用下で有色のキノンイミン化合物を生成し、その生成量は尿酸濃度と比例した。血清又は尿サンプルを採って、尿酸検出試薬キットの取り扱い説明に従い、キュベット光路1cm、540nm〜560nmの波長条件下で、空キュベットにより零位を校正し、紫外吸光光度計により吸光度を検出し、尿酸値を得た。
8.1)体重変化
正常群に比較して、実験の21日目に、モデル群のラット体重は有意に上昇した(P<0.05=。モデル群に比較して、実験期間中、各投与群のラット体重に有意差が認められなかった。表2及び図1に示す。
正常群に比較して、実験7日目、14日目、28日目、35日目にモデル群の血清UAレベルは有意に上昇し(P<0.05又はP<0.01)、高尿酸血症モデル作製が成功したと分かる。モデル群に比較して、実験14日目、28日目、35日目に、ベンズブロマロン群の血清UAレベルは有意に低下し(P<0.05)、実験14日目、21日目、28日目、35日目に、高用量群、中用量群、低用量群の血清UAレベルはすべて有意に低下した(P<0.05又はP<0.01)。表3及び図2に示す。
正常群に比較して、実験期間中、モデル群の血清BUNレベルに有意差が認められなかった(P>0.05)。モデル群に比較して、実験21日目、35日目に、高用量群の血清BUNレベルは有意に低下し(P<0.05又はP<0.01)、実験35日目に、中用量群、低用量群の血清BUNレベルは有意に低下した(P<0.05)。
正常群に比較して、実験期間中、モデル群の血清ADAレベルに有意差が認められなかった(P>0.05)。モデル群に比較して、実験21日目、高用量群の血清ADAレベルは有意に低下し(P<0.05)、実験35日目に、中用量群、低用量群の血清ADAレベルは有意に低下した(P<0.05又はP<0.01)。
実験35日目に、正常群に比較して、モデル群の24時間尿量は極めて有意に上昇し(P<0.01)、モデル群に比較して、各投与群に有意差が認められなかった(P>0.05)。正常群に比較して、モデル群の尿pHは極めて有意に低下し(P<0.01)、モデル群に比較して、中用量群尿pHは有意に上昇した(P<0.05)。表8、表9及び図8、図9に示す。
実験35日目に、正常群に比較して、モデル群の尿中UAレベルは有意に低下し(P<0.05)、モデル群に比較して、高用量群、中用量群、低用量群の尿中UAレベルは有意に低下した(P<0.01)。正常群に比較して、モデル群の尿中CREレベルは有意に低下し(P<0.01)、モデル群に比較して、中用量群の尿中CREレベルは有意に低下した(P<0.05)。正常群に比較して、モデル群の尿中BUNレベルは有意に低下し(P<0.01)、モデル群に比較して、各投与群に有意差が認められなかった(P>0.05)。
実験35日目に、正常群に比較して、モデル群の腎臓重量に有意差が認められず(P>0.05)、モデル群に比較して、各投与群の腎臓重量はすべて有意に上昇した(P<0.01)。表15及び図15に示す。
本発明は、SDラットに高フルクトース水を与えることで、安定した高尿酸血症モデルを作製した。実験期間中、ラット体内血清尿酸、クレアチニン、尿素窒素等の生化学的指標を動的にモニタニングし、本発明の抽出物の異なる投与量による尿酸降下作用を観察し、且つ尿酸産生及び尿酸排泄という2つの方面からその作用メカニズムを検討した。
2種の生薬の配合比を調整した以外に、実施例1の方法と同様に、下表16の生薬の配合比で異なる抽出物を調製した。次に、それぞれ実験例1及び実験例2の方法に照らし、これらの抽出物の投与後7日目、14日目、21日目といった測定日の尿酸降下百分率及びその平均血圧降下幅(%)を考察した。結果を表16に示す。
Claims (10)
- セロリ種子及び槐米をアルコール系溶媒中で抽出して得たことを特徴とする複合セロリ種子槐米抽出物。
- 前記セロリ種子と槐米との配合比は重量部で2:1〜4:1である請求項1に記載の複合セロリ種子槐米抽出物。
- 前記アルコール系溶媒はC1〜C4アルコール系溶媒から選択されるものであり、好ましくはメタノール、エタノール、イソプロパノール、n−ブタノールであり、より好ましくはエタノールである請求項1又は2に記載の複合セロリ種子槐米抽出物。
- 前記アルコール系溶媒はアルコール系水溶液であり、且つ該アルコール系水溶液の濃度は体積比率で50%〜80%であり、好ましくは50%〜70%である請求項3に記載の複合セロリ種子槐米抽出物。
- 抽出方法は超音波抽出法である請求項1〜4のいずれか1項に記載の複合セロリ種子槐米抽出物。
- 抽出時間は30分間〜60分間である請求項1〜5のいずれか1項に記載の複合セロリ種子槐米抽出物。
- 請求項1〜6のいずれか1項に記載の複合セロリ種子槐米抽出物、及び1種又は複数種の薬学的に許容される担体を含有する医薬組成物。
- 請求項1〜6のいずれか1項に記載の複合セロリ種子槐米抽出物又は請求項7に記載の医薬組成物の、血清アデノシンデアミナーゼ、キサンチンオキシダーゼ、グアノシンデアミナーゼのレベル上昇に起因する疾患を予防及び/又は治療するための薬物の調製への使用。
- 請求項1〜6のいずれかに記載の複合セロリ種子槐米抽出物又は請求項7に記載の医薬組成物の、高尿酸血症を予防及び/又は治療するための薬物の調製への使用。
- 請求項1〜6のいずれかに記載の複合セロリ種子槐米抽出物又は請求項7に記載の医薬組成物の、痛風を予防及び/又は治療するための薬物の調製への使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610313303.8 | 2016-05-12 | ||
CN201610313303.8A CN107362194B (zh) | 2016-05-12 | 2016-05-12 | 复方芹菜籽槐米提取物及其医药用途 |
PCT/CN2017/084073 WO2017193985A1 (zh) | 2016-05-12 | 2017-05-12 | 复方芹菜籽槐米提取物及其医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019515050A true JP2019515050A (ja) | 2019-06-06 |
JP6818972B2 JP6818972B2 (ja) | 2021-01-27 |
Family
ID=60266289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019512033A Active JP6818972B2 (ja) | 2016-05-12 | 2017-05-12 | 複合セロリ種子槐米抽出物及びその医薬用途 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3456336B8 (ja) |
JP (1) | JP6818972B2 (ja) |
KR (2) | KR20190003736A (ja) |
CN (1) | CN107362194B (ja) |
WO (1) | WO2017193985A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111529597A (zh) * | 2020-05-29 | 2020-08-14 | 广东众益康生物科技有限公司 | 一种用于痛风和/或高尿酸血症的中药组合物 |
CN115120631B (zh) * | 2021-03-26 | 2024-04-23 | 北京天衡军威医药技术开发有限公司 | 一种治疗痛风及高尿酸血症的药物组合物及其制备方法 |
CN113384607B (zh) * | 2021-06-30 | 2022-06-24 | 北京劲得健康科技有限公司 | 芹菜籽提取物及其在抗高尿酸血症和抗痛风产品中的应用 |
CN115607588B (zh) * | 2021-07-13 | 2023-11-17 | 北京天衡军威医药技术开发有限公司 | 一种标本兼治抗痛风的芹槐提取物与非布司他药物组合物及其用途 |
WO2023038287A1 (ko) * | 2021-09-10 | 2023-03-16 | 경북대학교 산학협력단 | 샐러리씨 추출물을 유효성분으로 포함하는 근력 약화 관련 질환 예방, 개선 또는 치료용 조성물 |
KR102507494B1 (ko) | 2021-09-10 | 2023-03-13 | 경북대학교 산학협력단 | 샐러리씨 추출물을 유효성분으로 포함하는 근력 약화 관련 질환 예방, 개선 또는 치료용 조성물 |
FR3134820A1 (fr) * | 2022-04-20 | 2023-10-27 | L'oreal | Concrete et absolue de parfum obtenues par extraction de solvant (poly)ol organique a partir de matieres naturelles solides |
CN115299602A (zh) * | 2022-06-29 | 2022-11-08 | 北京彩晔健康管理有限公司 | 一种降尿酸组合物及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100569241C (zh) | 2007-01-17 | 2009-12-16 | 北京天川军威医药技术开发有限公司 | 芹菜籽乙酸乙酯萃取物及其用途 |
CN101181345B (zh) * | 2007-11-15 | 2011-01-12 | 南京大学 | 槐米黄酮提取物在制备尿酸转运子urat1抑制药物中的应用 |
CN102048775B (zh) * | 2010-12-09 | 2012-11-07 | 北京人福军威医药技术开发有限公司 | 芹菜籽提取物的组合物及其制备方法 |
CN102008525B (zh) * | 2010-12-09 | 2012-11-28 | 北京人福军威医药技术开发有限公司 | 芹菜籽提取物的微丸及其制备方法 |
CN103947948B (zh) * | 2014-03-19 | 2015-12-30 | 桂玉平 | 一种槐花保健米糕及其加工方法 |
CN105535048A (zh) * | 2016-01-04 | 2016-05-04 | 中国科学院昆明植物研究所 | 芹菜籽提取物在制备抗高尿酸血症和抗痛风的药物或保健食品中的应用 |
-
2016
- 2016-05-12 CN CN201610313303.8A patent/CN107362194B/zh active Active
-
2017
- 2017-05-12 WO PCT/CN2017/084073 patent/WO2017193985A1/zh unknown
- 2017-05-12 KR KR1020187035068A patent/KR20190003736A/ko active Application Filing
- 2017-05-12 KR KR1020207035520A patent/KR102331984B1/ko active IP Right Grant
- 2017-05-12 EP EP17795603.4A patent/EP3456336B8/en active Active
- 2017-05-12 JP JP2019512033A patent/JP6818972B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6818972B2 (ja) | 2021-01-27 |
EP3456336A4 (en) | 2019-11-06 |
CN107362194B (zh) | 2020-08-25 |
EP3456336A1 (en) | 2019-03-20 |
WO2017193985A1 (zh) | 2017-11-16 |
KR20200142107A (ko) | 2020-12-21 |
KR102331984B1 (ko) | 2021-12-02 |
CN107362194A (zh) | 2017-11-21 |
EP3456336B1 (en) | 2021-07-21 |
EP3456336B8 (en) | 2021-10-06 |
KR20190003736A (ko) | 2019-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6818972B2 (ja) | 複合セロリ種子槐米抽出物及びその医薬用途 | |
JP4669920B2 (ja) | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 | |
KR102299934B1 (ko) | 숙취해소에 뛰어나며 알코올에 의한 간 손상을 예방 또는 치료용 조성물 | |
EP2829275A1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
EP3275451B1 (en) | Chinese medicine extract and preparation method and application thereof | |
CN106616177A (zh) | 一种具有降尿酸疗效的复合多肽固体饮料及其制备方法 | |
CN105878322A (zh) | 一种结晶酶解法制备的葵花盘提取物及其制备方法 | |
CN101785803A (zh) | 用于抑制环加氧酶和/或5-脂氧化酶的组合物 | |
KR20130107531A (ko) | 백합 추출물을 유효성분으로 함유하는 만성폐쇄성 폐질환 예방 및 치료용 약학적 조성물 | |
WO2002072123A1 (fr) | Compositions prophylactiques ou therapeutiques pour des maladies tumorales ou liees au papillomavirus | |
TWI395590B (zh) | 相思樹抽出物及其成分作為抑制黃嘌呤氧化酶之應用 | |
KR101890796B1 (ko) | 인삼열매 추출물, 헛개과병 추출물 및 미네랄 농축액을 함유하는 숙취 예방 또는 해소용 조성물 | |
WO2018151334A1 (ja) | キサンチンオキシダーゼ阻害剤及びその製造方法 | |
JP6151003B2 (ja) | カンカニクジュヨウから得られる抗糖尿病剤、ヒト又は動物用医薬および機能性食品 | |
EP3117825A1 (en) | Oral formulation comprising berberine and morus alba extract | |
JP2022040231A (ja) | キサンチンオキシダーゼ活性阻害用組成物 | |
JP4371431B2 (ja) | 抗アレルギー性組成物 | |
CN113456661A (zh) | 一种降尿酸的复合多糖组合物及其应用 | |
CN112587573A (zh) | 壮药五叶泡醇提物作为制备抗高尿酸血症药物的用途 | |
KR101928656B1 (ko) | 신장 보호 활성을 갖는 쿠드라트리쿠스잔톤 a를 유효성분으로 포함하는 신장 질환 예방 또는 치료용 조성물 | |
KR20160008135A (ko) | 개오동나무 추출물을 함유하는 숙취 예방 또는 해소용 조성물 | |
TW201927326A (zh) | 源自綠茶萃取物之發酵物的製造方法以及源自綠茶萃取物之麴發酵物、以及含有源自綠茶萃取物之麴發酵物的組成物 | |
JP2006016340A (ja) | ザクロ抽出物を有効成分とする、血中尿酸値低下剤 | |
KR102158661B1 (ko) | 밀양 반시의 미성숙 생감꼭지 추출물을 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물 | |
KR102633837B1 (ko) | 류마티스 관절염의 개선 및 치료 효능이 우수한 황금 추출물 및 황련 추출물의 혼합물 제조방법 및 상기 혼합물을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200814 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200820 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200911 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200916 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201007 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6818972 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |